within Pharmacolibrary.Drugs.ATC.P;

model P01CC01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0013333333333333333,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.089,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007750000000000001,
    Tlag           = 12.0,            
    Vdp             = 0.038,
    k12             = 108,
    k21             = 108
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01CC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nifurtimox is a nitrofuran derivative used primarily for the treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi. It has antiparasitic activity and is sometimes used off-label for other trypanosomal diseases. Nifurtimox has been approved for use in several countries, but is often reserved for cases where benznidazole is not available or appropriate.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after oral administration; data primarily from non-compartmental and compartmental PK studies.</p><h4>References</h4><ol><li><p>Schulz, SI, et al., &amp; Stass, H (2023). . <i>Current drug metabolism</i> 24(8) 599–610. DOI:<a href=\"https://doi.org/10.2174/1389200224666230817114758\">10.2174/1389200224666230817114758</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37592798/\">https://pubmed.ncbi.nlm.nih.gov/37592798</a></p></li><li><p>Lang, D, et al., &amp; Stass, H (2022). Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox. <i>Chemical research in toxicology</i> 35(11) 2037–2048. DOI:<a href=\"https://doi.org/10.1021/acs.chemrestox.2c00210\">10.1021/acs.chemrestox.2c00210</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36209416/\">https://pubmed.ncbi.nlm.nih.gov/36209416</a></p></li><li><p>Amilon, C, et al., &amp; Jansson-Löfmark, R (2022). Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. <i>The AAPS journal</i> 24(3) 48–None. DOI:<a href=\"https://doi.org/10.1208/s12248-022-00693-2\">10.1208/s12248-022-00693-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35338410/\">https://pubmed.ncbi.nlm.nih.gov/35338410</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01CC01;
